Avodart, Dutasteride News

Medical advances can be slow -- a fact frustrating to some who want the "latest and greatest" cure for their ailment, and don't want to wait out the testing process.

This isn't a story about losing your hair gracefully. Instead, it's about men like Chuck, a successful lawyer, who in his early twenties looked in the mirror and was mortified to see the hair on his temples thinning.

There is a hair loss baldness treatment available for different people. However, the first step in dealing with hair loss is to consult with a doctor and to get a complete medical examination.

A large clinical trial has found that the drug Avodart reduces the risk of prostate cancer.

An administration official says a presidential Boeing 747 and a fighter jet flew low near ground zero in New York City on Monday because the White House Military Office wanted to update its file photo of the president's plane near the Statue of Liberty.

Main Category: Prostate / Prostate Cancer Also Included In: Urology / Nephrology Pharma Industry / Biotech Industry Headline data from the REduction by DUtasteride of prostate Cancer Events trial was presented at the American Urological Association in Chicago, Illinois today.

GlaxoSmithKline , the UK-based pharmaceutical group, received a boost from data that could extend the use of one of its medicines to prevent prostate cancer.

An initial analysis of the finasteride data suggested that there was an increased risk for men to have prostate cancer with higher Gleason scores but a later analysis suggested that there is probably no greater risk for these men to develop higher grade prostate cancer.

The recent announcement of the REDUCE trial results at the American Urological Association annual meeting in Chicago brings optimism to the prostate cancer community as dutasteride , a drug used to treat benign prostatic hyperplasia, has shown to lower by 23 percent the risk of prostate cancer in men with an increased risk of the disease.

REDUCE Trial data presented during American Urological Association Annual Meeting, April 27 CHICAGO, April 28 /PRNewswire-USNewswire/ -- Dutasteride , a commonly prescribed drug to treat benign prostatic hyperplasia, has been shown to lower the risk of prostate cancer by 23 percent in men with an increased risk of the disease, according to results ...

Avodart, a drug from GlaxoSmithKline , reduces the risk of prostate cancer , results of a large clinical study showed on Monday.

GlaxoSmithKline PLC's Avodart cuts the risk of prostate cancer . In the study, which involved 8,231 patients with increased risk of prostate cancer, 22.5% of men taking Avodart were diagnosed with prostate cancer after four years, compared with 29% who were taking a placebo.

A drug already sold for other prostate problems significantly cut the chances of prostate cancer being found in men with an increased risk of the disease, doctors reported Monday.

The American Urological Association will offer journalists the opportunity to hear from world-renowned experts about prostate cancer screening and prevention during a special expert panel session on April 27, 2009 at 12:15 p.m. Authors representing the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, the European Randomised Study of ...

Discontinuing combination therapy for benign prostate hyperplasia leads to increased prostate volume and worsening of symptoms, according to a study in the April issue of Urology .

Use of a biodegradable braided urethral stent along with dutasteride therapy shows promise in treatment of acute urinary retention in men with benign prostatic enlargement, according to Finnish researchers.

UroToday.com - In the online edition of the journal Prostate, Dr. Francesco Montorsi and a group of European colleagues reviewed the expanding use of 5-alpha reductase inhibitors in prostate diseases.

FDA, last week, posted a letter sent to GlaxoSmithKline requesting that the firm stop running a television spot for its prostate treatment Avodart .

The Food and Drug Administration has admonished GlaxoSmithKline , calling an ad for its prostate drug Avodart misleading.

Michele M. Hardy Senior Director, U.S. Regulatory Affairs, GlaxoSmithKline P.O. Box 13398 Five Moore Drive Research Triangle Park, NC 27709 RE: NDA 21-319 AVODART Soft Gelatin Capsules MACMIS # 17228 Dear Ms.